There are no established relationships between GRIN2A and obesity-related phenotypes in the literature, yet memantine and ketamine, pharmacological antagonists of GRIN2A activity34, 35, are implicated in treatment for obesity-associated disorders, including binge-eating disorders and morbid obesity (ClinicalTrials.gov identifiers: NCT00330655, NCT02334059, NCT01997515, NCT01724983). This evidence concerns the gene GRIN2A and morbid obesity.